0000950170-23-053183.txt : 20231012
0000950170-23-053183.hdr.sgml : 20231012
20231012201926
ACCESSION NUMBER: 0000950170-23-053183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231010
FILED AS OF DATE: 20231012
DATE AS OF CHANGE: 20231012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maduck Sean
CENTRAL INDEX KEY: 0001698310
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 231323667
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2023-10-10
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001698310
Maduck Sean
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
See Remarks
true
Common Stock
2023-10-10
4
M
false
8471
3.02
A
82081
D
Common Stock
2023-10-10
4
M
false
10000
2.61
A
92081
D
Common Stock
2023-10-10
4
S
false
18471
27.2881
D
73291
D
Common Stock
10000
I
See Footnote
Common Stock
10000
I
See Footnote
Stock option (right to buy)
3.02
2023-10-10
4
M
false
8471
0.00
D
2024-02-06
Common Stock
8471
0
D
Stock option (right to buy)
2.61
2023-10-10
4
M
false
10000
0.00
D
2024-08-07
Common Stock
10000
45009
D
Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.435. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
The Form 4 previously filed inadvertently overstated the number of shares held by 319. The number in Column 5 reflects the corrected amount.
Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
Fully exercisable.
President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
2023-10-12